Y-mabs announces presentation of sada technology at aacr

New york, april 08, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring preclinical data from its gd2 sada construct will be presented at the aacr annual meeting 2022, which takes place in new orleans, louisiana from april 8-13, 2022.
YMAB Ratings Summary
YMAB Quant Ranking